TCRX – tscan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.
City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference [Yahoo! Finance]
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
Form 4 TScan Therapeutics, Inc. For: Dec 12 Filed by: Nichols Weston
Form 8-K TScan Therapeutics, Inc. For: Dec 09
Form 8-K TScan Therapeutics, Inc. For: Nov 15
Form 4 TScan Therapeutics, Inc. For: Nov 15 Filed by: Nichols Weston
Form SC 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.